PanTHer Therapeutics Closes $5.4M in Series A Funding
- PanTher Therapeutics, a Cambridge MA-based company advancing treatments for solid tumors, raised $5.4M in Series A funding
- The round was led by Catalyst Health Ventures (CHV), with participation from Angel Physicians Fund (APF) and other notable investors
- The company intends to use the funds to expands its development efforts and to initiate first clinical trial of novel localized treatment of pancreatic cancer
- PanTher is an oncology company advancing new treatments for solid tumors through direct, localized, and sustained delivery of proven and novel therapeutic agents
- The company’s lead candidate is designed to control tumor progression in pancreatic cancer and is integrated into a commonly used, minimally invasive staging procedure
- PanTher’s platform technology can be adapted to treat additional solid tumor indications
